• LAST PRICE
    56.0000
  • TODAY'S CHANGE (%)
    Trending Down-1.6500 (-2.8621%)
  • Bid / Lots
    55.8900/ 4
  • Ask / Lots
    56.0000/ 4
  • Open / Previous Close
    57.2400 / 57.6500
  • Day Range
    Low 55.2800
    High 58.1500
  • 52 Week Range
    Low 19.8050
    High 61.6100
  • Volume
    75,669
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 57.65
TimeVolumeMRUS
09:32 ET618158.14
09:34 ET220057.165
09:36 ET94757.61
09:38 ET154556.97
09:41 ET200056.72
09:43 ET20056.8
09:45 ET696456.965
09:48 ET90056.52
09:50 ET30056.56
09:52 ET246256.45
09:54 ET289756.08
09:56 ET144055.805
09:57 ET50055.78
09:59 ET10055.78
10:01 ET50055.68
10:03 ET202955.45
10:06 ET222055.41
10:08 ET35055.34
10:10 ET355055.64
10:12 ET26055.705
10:14 ET50055.58
10:15 ET40055.35
10:17 ET30055.51
10:19 ET30055.44
10:21 ET139055.44
10:24 ET20055.49
10:26 ET209855.57
10:28 ET72455.59
10:32 ET10055.69
10:33 ET40055.605
10:35 ET40055.665
10:37 ET70055.64
10:39 ET60055.725
10:42 ET160055.775
10:46 ET30055.775
10:51 ET70055.775
10:53 ET304755.8
10:57 ET10055.9
11:00 ET30055.9
11:02 ET412856
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesMRUS
Merus NV
3.8B
-20.6x
---
United StatesCRNX
Crinetics Pharmaceuticals Inc
3.8B
-12.2x
---
United StatesIBRX
Immunitybio Inc
3.9B
-5.6x
---
United StatesIMVT
Immunovant Inc
3.7B
-13.8x
---
United StatesRNA
Avidity Biosciences Inc
3.7B
-13.5x
---
United StatesALVO
Alvotech SA
4.3B
-6.9x
---
As of 2024-06-14

Company Information

Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.

Contact Information

Headquarters
Uppsalalaan 17, 3rd & 4th floorUTRECHT, Netherlands 3584 CT
Phone
---
Fax
---

Executives

Non-Executive Independent Chairman of the Board
Anand Mehra
President, Chief Executive Officer, Executive Director
Sven Lundberg
Chief Financial Officer
Gregory Perry
Chief Operating Officer, General Counsel, Chief Intellectual Property Officer and Head of US Legal
Peter Silverman
Chief Medical Officer
Andrew Joe

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$3.8B
Revenue (TTM)
$38.3M
Shares Outstanding
67.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.12
EPS
$-2.72
Book Value
$6.16
P/E Ratio
-20.6x
Price/Sales (TTM)
99.6
Price/Cash Flow (TTM)
---
Operating Margin
-434.58%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.